Artificial Intelligence-Focused Companies Advance Programming BioSpace

The use of artificial intelligence and machine learning is almost commonplace in the biotech and pharma industry as multiple companies are harnessing the power to aid in drug discovery and development. This week more companies have announced advancements in their AI programming. This morning, San Francisco-based Notable Labs announced it secured $40 million in a Series B funding round to use its artificial intelligence platform to advance cancer drug development. The company's approach is aimed at predicting which types of patients are most likely to respond to a drug in as little as five days. The process is designed to help physicians make more informed decisions about which clinical trials will be effective with patients and can also benefit the likelihood of a trial's success by matching the right patients to the right trial.